These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 22969248)

  • 21. Concomitant EGFR Mutation and EML4-ALK Rearrangement in Lung Adenocarcinoma Is More Frequent in Multifocal Lesions.
    Fan J; Dai X; Wang Z; Huang B; Shi H; Luo D; Zhang J; Cai W; Nie X; Hirsch FR
    Clin Lung Cancer; 2019 Jul; 20(4):e517-e530. PubMed ID: 31138506
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Expression of ALK protein in 7 371 pulmonary adenocarcinoma samples, with analysis of clinicopathologic features].
    Zhao RY; Zhang J; Zhu L; Shao JC; Zhang Q; Teng HH; Qin G; Zhao LX; Ye M; Zhao JK; Ding WJ
    Zhonghua Bing Li Xue Za Zhi; 2016 Sep; 45(9):601-5. PubMed ID: 27646887
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Survival Benefit of Pemetrexed in Lung Adenocarcinoma Patients With Anaplastic Lymphoma Kinase Gene Rearrangements.
    Park S; Park TS; Choi CM; Lee DH; Kim SW; Lee JS; Kim WS; Song JS; Lee JC
    Clin Lung Cancer; 2015 Sep; 16(5):e83-9. PubMed ID: 25682546
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Nrf2 and Keap1 Abnormalities in 104 Lung Adenocarcinoma Cases and Association with Clinicopathologic Features].
    Xiao Y; Zhu X; Gu Y; Chen S; Liang L; Cao B
    Zhongguo Fei Ai Za Zhi; 2018 Mar; 21(3):241-250. PubMed ID: 29587953
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Gene status and clinicopathologic characteristics of lung adenocarcinomas with mediastinal lymph node metastasis.
    Zhang S; Yan B; Zheng J; Zhao J; Zhou J
    Oncotarget; 2016 Sep; 7(39):63758-63766. PubMed ID: 27563816
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Metabolic phenotype of stage IV lung adenocarcinoma: relationship with epidermal growth factor receptor mutation.
    Lee EY; Khong PL; Lee VH; Qian W; Yu X; Wong MP
    Clin Nucl Med; 2015 Mar; 40(3):e190-5. PubMed ID: 25608155
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinicopathologic implication of ALK rearrangement in surgically resected lung cancer: a proposal of diagnostic algorithm for ALK-rearranged adenocarcinoma.
    Paik JH; Choi CM; Kim H; Jang SJ; Choe G; Kim DK; Kim HJ; Yoon H; Lee CT; Jheon S; Choe JY; Chung JH
    Lung Cancer; 2012 Jun; 76(3):403-9. PubMed ID: 22129856
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Unique clinicopathologic features characterize ALK-rearranged lung adenocarcinoma in the western population.
    Rodig SJ; Mino-Kenudson M; Dacic S; Yeap BY; Shaw A; Barletta JA; Stubbs H; Law K; Lindeman N; Mark E; Janne PA; Lynch T; Johnson BE; Iafrate AJ; Chirieac LR
    Clin Cancer Res; 2009 Aug; 15(16):5216-23. PubMed ID: 19671850
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical characteristics of patients with non-small cell lung cancers harboring anaplastic lymphoma kinase rearrangements and primary lung adenocarcinoma harboring epidermal growth factor receptor mutations.
    Xu L; Lei J; Wang QZ; Li J; Wu L
    Genet Mol Res; 2015 Oct; 14(4):12973-83. PubMed ID: 26505450
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Frequency of driver mutations in lung adenocarcinoma from female never-smokers varies with histologic subtypes and age at diagnosis.
    Zhang Y; Sun Y; Pan Y; Li C; Shen L; Li Y; Luo X; Ye T; Wang R; Hu H; Li H; Wang L; Pao W; Chen H
    Clin Cancer Res; 2012 Apr; 18(7):1947-53. PubMed ID: 22317764
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Driven Gene in Patients with Lung Squamous Cell Carcinoma: 
Analysis of Clinicopathologic Characteristics and Prognosis].
    Zhang T; Li J
    Zhongguo Fei Ai Za Zhi; 2016 Oct; 19(10):648-652. PubMed ID: 27760592
    [TBL] [Abstract][Full Text] [Related]  

  • 32. High prevalence of ALK+/ROS1+ cases in pulmonary adenocarcinoma of adoloscents and young adults.
    Scarpino S; Rampioni Vinciguerra GL; Di Napoli A; Fochetti F; Uccini S; Iacono D; Marchetti P; Ruco L
    Lung Cancer; 2016 Jul; 97():95-8. PubMed ID: 27237034
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Is there a progression-free survival benefit of first-line crizotinib versus standard chemotherapy and second-line crizotinib in ALK-positive advanced lung adenocarcinoma? A retrospective study of Chinese patients.
    Cui S; Zhao Y; Dong L; Gu A; Xiong L; Qian J; Zhang W; Niu Y; Pan F; Jiang L
    Cancer Med; 2016 Jun; 5(6):1013-21. PubMed ID: 26880708
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Serum carcinoembryonic antigen levels before initial treatment are associated with EGFR mutations and EML4- ALK fusion gene in lung adenocarcinoma patients.
    Wang WT; Li Y; Ma J; Chen XB; Qin JJ
    Asian Pac J Cancer Prev; 2014; 15(9):3927-32. PubMed ID: 24935562
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Role of imaging biomarkers in predicting anaplastic lymphoma kinase-positive lung adenocarcinoma.
    Jeong CJ; Lee HY; Han J; Jeong JY; Lee KS; Choi YL; Choi JY
    Clin Nucl Med; 2015 Jan; 40(1):e34-9. PubMed ID: 25243942
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Anaplastic lymphoma kinase (ALK)-expressing Lung Adenocarcinoma with Combined Neuroendocrine Component or Neuroendocrine Transformation: Implications for Neuroendocrine Transformation and Response to ALK-tyrosine Kinase Inhibitors.
    Sim J; Kim H; Hyeon J; Choi Y; Han J
    J Korean Med Sci; 2018 Apr; 33(15):e123. PubMed ID: 29629521
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinicopathological and prognostic significance of programmed cell death ligand-1 expression in lung adenocarcinoma and its relationship with p53 status.
    Cha YJ; Kim HR; Lee CY; Cho BC; Shim HS
    Lung Cancer; 2016 Jul; 97():73-80. PubMed ID: 27237031
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comprehensive study of mutational and clinicopathologic characteristics of adenocarcinoma with lepidic pattern in surgical resected lung adenocarcinoma.
    Xu Y; Zhu C; Qian W; Zheng M
    J Cancer Res Clin Oncol; 2017 Jan; 143(1):181-186. PubMed ID: 27738759
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Clinical features of 54 cases of lung adenocarcinomas with c-ROS oncogene 1 fusion].
    Cao H; Zheng J; Zhao J; Guo XJ; Zhou JY; Ding W; Zhou JY
    Zhonghua Jie He He Hu Xi Za Zhi; 2020 Feb; 43(2):120-125. PubMed ID: 32062881
    [No Abstract]   [Full Text] [Related]  

  • 40. CT features associated with EGFR mutations and ALK positivity in patients with multiple primary lung adenocarcinomas.
    Han X; Fan J; Gu J; Li Y; Yang M; Liu T; Li N; Zeng W; Shi H
    Cancer Imaging; 2020 Jul; 20(1):51. PubMed ID: 32690092
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.